Ology Bioservices, Inc.

Industry

  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Large Molecule
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Nasal
      • Pulmonary
      • Macromolecule
      • Controlled Release
      • Topical Delivery
  • Services
    • Consulting Services
  • Distributors
  • Contract Research Organization-CRO

Other Names/Subsidiaries

  • Vion Pharmaceuticals
  • Nanotherapeutics, Inc
See more in Biomedtracker

Latest on Ology Bioservices, Inc.

Scrip

Finance Watch: Resilience Raises $625m, Bringing New Cash To $1.2bn

 
• By Mandy Jackson

National Resilience, Inc. has closed a $625m series D venture capital round, bringing its total VC funding during the past 10 months to more than $1.2bn, including a previously unannounced $600m seri

In Vivo

Execs On The Move, July 2017

 
• By Regina Paleski

Company Changes AGARWAL , Sunil, MD To: Juno Therapeutics Inc. , Pres., R&D (April) From: Ultragenyx Pharmaceutical Inc., EVP, CMO Phone: 206-582-1600 AL-WAKEEL Yasir To: Neon Therapeutics

In Vivo

Execs On The Move, January 2017

 
• By Regina Paleski

Company Changes ALLEN , Jon To: Alphatec Holdings Inc. , EVP, Commercial Ops. (December) From: Wright Medical Group NV, VP, Healthcare Economics & Reimbursement Phone: 760-431-9286 ANDERSON ,

Scrip

Pfizer To Take Zinplava Rival Into Phase III For C Diff

 
• By Alex Shimmings

Top-line data for Pfizer Inc. ’s investigational vaccine PF-06425090 for the prevention of Clostridium difficile infection from a pre-planned interim analysis are strong enough to warrant taking